Results 101 to 110 of about 5,633 (190)

Publication Only

HemaSphere, Volume 10, Issue S1, June 2026.
wiley   +1 more source

Cardiovascular safety of febuxostat. Analysis of the CARES study

, 2018
Gout is associated with the high frequency of comorbidities, among which there are cardiovascular disease and kidney diseases. In this case, cardiovascular mortality rates are in the first place among the causes of death in patients with gout and exceed ...
M. S. Eliseev
core   +1 more source

Febuxostat.

Australian prescriber, 2015
  +7 more sources

Cardiovascular safety of febuxostat versus allopurinol among the Asian patients with or without gout: A systematic review and meta‐analysis

Clinical and Translational Science
The cardiovascular (CV) safety of febuxostat compared to allopurinol for the treatment of hyperuricemia among Asian patients is uncertain. In this study, we conducted a systematic review and meta‐analysis to compare the CV safety profiles of febuxostat ...
Jian‐hao Deng, Peng‐hui Lai, Li‐shan Xie, Shu‐sheng Qiu, De‐sheng Qiu, Jia‐xing Zhang   +5 more
doaj   +1 more source

Assessment of Cardiovascular Risk in Older Patients With Gout Initiating Febuxostat Versus Allopurinol

, 2018
Background: Hyperuricemia and gout are associated with an increased risk of cardiovascular disease. Xanthine oxidase inhibitors, allopurinol and febuxostat, are the mainstay of urate-lowering treatment for gout and may have ...
Tuhina Neogi, Seoyoung C. Kim, MaryAnn Zhang, Jun Liu, Rishi J. Desai, Eun Ha Kang, Daniel H. Solomon   +6 more
core   +1 more source

Comparative assessment of the effects of dotinurad and febuxostat on the renal function in chronic kidney disease patients with hyperuricemia

Scientific Reports
Although hyperuricemia is associated with chronic kidney disease (CKD), the impact of uric acid (UA)-lowering drugs on CKD has been controversial.
Tomoaki Takata, Sosuke Taniguchi, Yukari Mae, Kana Kageyama, Yudai Fujino, Takuji Iyama, Katsuya Hikita, Takaaki Sugihara, Hajime Isomoto   +8 more
doaj   +1 more source

Predictors of reaching a serum uric acid goal in patients with gout and treated with febuxostat

ClinicoEconomics and Outcomes Research, 2017
Richard Sheer,1 Kyle D Null,2 Keith A Szymanski,2 Lavanya Sudharshan,1 Jennifer Banovic,2 Margaret K Pasquale1 1Comprehensive Health Insights, Inc., Louisville, KY, 2Takeda Pharmaceuticals U.S.A., Inc., Deerfield, IL, USA Purpose: Clinical guidelines ...
Sheer R, Null KD, Szymanski KA, Sudharshan L, Banovic J, Pasquale MK   +5 more
doaj  

Comparisons of Therapeutic Effects of Allopurinol and Febuxostat in Chronic Hemodialysis Patients

, 2019
More than few patients on maintenance hemodialysis present with hyperuricemia, and the control of serum uric acid level is an important issue in the long-term management.
Murayama, Yoshiki, Onoda, Shou, Furuichi, Masahito, Ohira, Takehiro, Nagase, Akihiko, Ishimitsu, Toshihiko, Tojo Akihiro   +6 more
core  

Febuxostat [PDF]

, 2020
openaire   +1 more source

Febuxostat alleviates testicular dysfunction induced by cyclophosphamide in rats via modulation of pyroptosis and mTOR autophagy axis. [PDF]

Sci Rep
Atia HA, Elariny HA, Abdallah MH, Khalifa AM, Hellal D, Alghubayshi A, Kabel AM.   +6 more
europepmc   +1 more source